Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_provenance.
- NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_assertion description "[The various reports of dramatic and prolonged responses in brain metastases patients treated with EGFR and ALK TKIs suggest that these agents may be a valid treatment option for patients with asymptomatic brain metastases from NSCLC, especially for those with EGFR-activating mutations or harboring ALK rearrangement.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_provenance.
- NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_assertion evidence source_evidence_literature NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_provenance.
- NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_assertion SIO_000772 26504000 NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_provenance.
- NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_assertion wasDerivedFrom befree-2016 NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_provenance.
- NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_assertion wasGeneratedBy ECO_0000203 NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_provenance.
- befree-2016 importedOn "2016-02-19" NP1295230.RAVJolwyAcOe52pRbmBs9mLJeS-3AcQBM5gMXxOH_8jxk130_provenance.